BAY 3401016 / Bayer, Evotec - LARVOL DELTA

ASSESS: A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome (clinicaltrials.gov) - P2 | N=60 | Active, not recruiting | Sponsor: Bayer | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders

ASSESS: A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Bayer | Trial completion date: Jul 2028 ➔ Nov 2027 | Trial primary completion date: Jul 2028 ➔ Nov 2027

Trial completion date • Trial primary completion date • Genetic Disorders

ASSESS: A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Bayer | -> Recruiting | N=12 ➔ 60

Enrollment change • Enrollment open • Genetic Disorders

ASSESS: BAY3401016; Biomarker Study Alport (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Bayer | Not yet recruiting ➔ Recruiting

Biomarker • Enrollment open • Genetic Disorders

22419: A study to learn about how well BAY 3401016 works in adults with Alport syndrome (clinicaltrialsregister.eu) - P1/2 | N=31 | Recruiting | Sponsor: Bayer AG

New P1/2 trial • Chronic Kidney Disease • Genetic Disorders • Nephrology • Renal Disease

ASSESS: BAY3401016; Biomarker Study Alport (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Bayer

Biomarker • New P2 trial • Genetic Disorders